Funding for gene therapy to injured peripheral nerves

(University of Plymouth) Scientists from Plymouth University Peninsula Schools of Medicine and Dentistry have received funding from the Northcott Devon Medical Foundation to explore the potential of gene therapy as a way to enhance functional recovery following microsurgery for injured peripheral nerves.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Downregulation of hypoxia‑inducible factor-1α inhibits growth, invasion, and angiogenesis of human salivary adenoid cystic carcinoma cells under hypoxia. Oncol Rep. 2018 Jul 12;: Authors: Xiao C, Pan Y, Zeng X, Wang L, Li Z, Yan S, Wang H Abstract Surgical and medical treatments usually fail to completely remove the primary lesions of salivary adenoid cystic carcinoma (SACC), resulting in local recurrence due to its strong infiltration, hematogenous metastasis and other unique biological behaviors. Targeted gene therapy, including hypoxia‑inducible factor‑1α (HIF‑1α) therapy, ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Xin G, Chen R, Zhang X Abstract The aim of the present study was to explore the candidate genes, chemicals and mechanisms of congenital obstructive nephropathy (CON). The gene expression profiles of GSE48041, including 24 kidney tissue samples from megabladder (mgb‑/‑) mouse were downloaded from the Gene Expression Omnibus database. Samples were divided into 4 groups: Control, mild, moderate and severe. Differentially expressed genes (DEGs), protein‑protein interaction network, Kyoto Encyclopedia of Genes and Genomes pathways and transcription factor (TF)‑target gene analyses were perform...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Identification of a novel idiopathic congenital nystagmus‑causing missense mutation, p.G296C, in the FRMD7 gene. Mol Med Rep. 2018 Jul 09;: Authors: Xiu Y, Yao Y, Yang T, Pan M, Yang H, Fang W, Gu F, Zhao J, Zhu Y Abstract Exploring the genetic basis for idiopathic congenital nystagmus is critical for improving our understanding of its molecular pathogenesis. In the present study, direct sequencing using gene specific primers was performed in order to identify the causative mutations in two brothers from a Chinese family who had been diagnosed with idiopathic congenital nystagmus. A comprehensive oph...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 17 July 2018Source: Regulatory Toxicology and PharmacologyAuthor(s): Frank R. Brennan, Laura Andrews, Antonio R. Arulanandam, Jorg Blumel, Jim Fikes, Christine Grimaldi, Janice Lansita, Lise I. Loberg, Tim MacLachlan, Mark Milton, Suezanne Parker, Jay Tibbitts, Jayanthi Wolf, Krishna P. AllamneniAbstractNonclinical safety testing of biopharmaceuticals can present significant challenges to human risk assessment with these innovative and often complex drugs. Emerging topics in this field were discussed recently at the 2016 Annual US BioSafe General Membership meeting. The presentations and ...
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research
The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins, Published online: 18 July 2018; doi:10.1038/s41434-018-0025-8The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
Source: Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Abstract Sensorineural hearing loss is caused by the loss of sensory hair cells (HCs) or a damaged afferent nerve pathway to the auditory cortex. The most common option for the treatment of sensorineural hearing loss is hearing rehabilitation using hearing devices. Various kinds of hearing devices are available but, despite recent advancements, their perceived sound quality does not mimic that of the "naïve" cochlea. Damage to crucial cochlear structures is mostly irreversible and results in permanent hearing loss. Cochlear HC regeneration has long been an important goal in the field of hearing rese...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Oisin Biotechnologies is the company working on what is, to my eyes, the best of the best when it comes to the current crop of senolytic technologies, approaches capable of selectively destroying senescent cells in old tissues. Adding senescent cells to young mice has been shown to produce pathologies of aging, and removal of senescent cells can reverse those pathologies, and also extend life span. It is a very robust and reliable approach, with these observations repeated by numerous different groups using numerous different methodologies of senescent cell destruction. Most of the current senolytic development prog...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs
Condition:   Hemophilia A Intervention:   Drug: BAY2599023 (DTX201) Sponsors:   Bayer;   Dimension Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
.
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Source Type: research
Pfizer Inc. said Monday it has started late-stage clinical testing of an experimental gene therapy treatment, originally developed by Spark Therapeutics in Philadelphia, for patients with hemophilia B. The transfer of the gene therapy program to Pfizer from Spark is now complete, the companies said. Under the terms of a product license agreement signed in December 2014, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, all regulatory activities, manufacturing and gl obal…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Dentistry | Funding | Gene Therapy | Genetics | International Medicine & Public Health | Schools